FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4303983644> ?p ?o ?g. }

• W4303983644 endingPage "10" @default.
• W4303983644 startingPage "10" @default.
• W4303983644 abstract "Background: The optimal treatment for patients with early-stage nodular-lymphocyte predominant Hodgkin lymphoma (NLPHL) other than stage IA is undefined. Patients and Methods: We investigated characteristics and outcomes of patients with early-stage NLPHL (favorable: 85 patients; unfavorable: 15 patients) who had treatment within the randomized GHSG HD16 and HD17 studies. Results were compared to those from patients with classical Hodgkin lymphoma (cHL) (favorable: 495 patients; unfavorable: 764 patients) treated within the same studies. Chemotherapy consisted of 2 cycles of ABVD (HD16) or 2 cycles of escalated BEACOPP plus 2 cycles of ABVD („2 + 2“) (HD17). In the experimental study arms, consolidation radiotherapy (RT) was applied on the basis of the result of interim positron emission tomography (PET-2). In the standard arms, consolidation RT was mandatory. Progression-free survival (PFS) and overall survival (OS) were analyzed using the Kaplan-Meier method. Results: In the HD16 and HD17 studies, 62/85 (73%) and 13/15 (87%) NLPHL patients were male as compared to 254/495 (51%) and 337/764 (44%) cHL patients. The median age of patients with NLPHL was 37 years in the HD16 study (cHL: 36 years) and 42 years in the HD17 study (cHL: 31 years). The majority of NLPHL patients included in the HD16 and HD17 studies presented with a typical histopathological growth pattern (HD16: 66%; HD17: 70%) The 5-year PFS for all NLPHL patients was 90.3% (cHL: 90.8%) in the HD16 study and 92.9% (cHL: 95.7%) in the HD17 study. In the HD16 study, the 5-year PFS for the subgroup of PET-2-positive NLPHL patients was 89.3% (cHL: 91.6%); PET-2-negative NLPHL patients had a 5-year PFS of 91.0% (cHL: 90.4%). For PET-2-negative NLPHL patients assigned to the chemotherapy only arm, the 5-year PFS was 83.0% (cHL: 88.2%) whereas PET-2-negative NLPHL patients treated with chemotherapy plus RT had a 5-year PFS of 100% (cHL: 92.3%) (p=0.05). Subgroup analyses according to the PET-2 result were not conducted for NLPHL patients treated within the HD17 study due to the small number of individuals with NLPHL histology included in this trial. The 5-year OS for NLPHL patients treated within the HD16 and HD17 studies was 100% (cHL: 98.6% in HD16; 99.2% in HD17). Conclusion: Contemporary HL-directed treatment results in excellent 5-year outcomes for patients with newly diagnosed early-stage NLPHL and should thus be considered as valid approach for this patient group." @default.
• W4303983644 created "2022-10-10" @default.
• W4303983644 creator A5003363227 @default.
• W4303983644 creator A5019245327 @default.
• W4303983644 creator A5027551270 @default.
• W4303983644 creator A5039994927 @default.
• W4303983644 creator A5053252307 @default.
• W4303983644 creator A5055488306 @default.
• W4303983644 creator A5064132655 @default.
• W4303983644 creator A5068013617 @default.
• W4303983644 creator A5071228709 @default.
• W4303983644 creator A5075117420 @default.
• W4303983644 creator A5076460303 @default.
• W4303983644 date "2022-10-01" @default.
• W4303983644 modified "2023-10-08" @default.
• W4303983644 title "T020: Interim PET-guided treatment of early-stage nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the GHSG HD16 and HD17 studies" @default.
• W4303983644 doi "https://doi.org/10.1097/01.hs9.0000890648.99383.b7" @default.
• W4303983644 hasPublicationYear "2022" @default.
• W4303983644 type Work @default.
• W4303983644 citedByCount "0" @default.
• W4303983644 crossrefType "journal-article" @default.
• W4303983644 hasAuthorship W4303983644A5003363227 @default.
• W4303983644 hasAuthorship W4303983644A5019245327 @default.
• W4303983644 hasAuthorship W4303983644A5027551270 @default.
• W4303983644 hasAuthorship W4303983644A5039994927 @default.
• W4303983644 hasAuthorship W4303983644A5053252307 @default.
• W4303983644 hasAuthorship W4303983644A5055488306 @default.
• W4303983644 hasAuthorship W4303983644A5064132655 @default.
• W4303983644 hasAuthorship W4303983644A5068013617 @default.
• W4303983644 hasAuthorship W4303983644A5071228709 @default.
• W4303983644 hasAuthorship W4303983644A5075117420 @default.
• W4303983644 hasAuthorship W4303983644A5076460303 @default.
• W4303983644 hasBestOaLocation W43039836441 @default.
• W4303983644 hasConcept C126322002 @default.
• W4303983644 hasConcept C143998085 @default.
• W4303983644 hasConcept C146357865 @default.
• W4303983644 hasConcept C151730666 @default.
• W4303983644 hasConcept C166957645 @default.
• W4303983644 hasConcept C2776305933 @default.
• W4303983644 hasConcept C2776694085 @default.
• W4303983644 hasConcept C2776755627 @default.
• W4303983644 hasConcept C2776957806 @default.
• W4303983644 hasConcept C2779338263 @default.
• W4303983644 hasConcept C2779429289 @default.
• W4303983644 hasConcept C2989005 @default.
• W4303983644 hasConcept C2992779791 @default.
• W4303983644 hasConcept C509974204 @default.
• W4303983644 hasConcept C71924100 @default.
• W4303983644 hasConcept C86803240 @default.
• W4303983644 hasConcept C95457728 @default.
• W4303983644 hasConceptScore W4303983644C126322002 @default.
• W4303983644 hasConceptScore W4303983644C143998085 @default.
• W4303983644 hasConceptScore W4303983644C146357865 @default.
• W4303983644 hasConceptScore W4303983644C151730666 @default.
• W4303983644 hasConceptScore W4303983644C166957645 @default.
• W4303983644 hasConceptScore W4303983644C2776305933 @default.
• W4303983644 hasConceptScore W4303983644C2776694085 @default.
• W4303983644 hasConceptScore W4303983644C2776755627 @default.
• W4303983644 hasConceptScore W4303983644C2776957806 @default.
• W4303983644 hasConceptScore W4303983644C2779338263 @default.
• W4303983644 hasConceptScore W4303983644C2779429289 @default.
• W4303983644 hasConceptScore W4303983644C2989005 @default.
• W4303983644 hasConceptScore W4303983644C2992779791 @default.
• W4303983644 hasConceptScore W4303983644C509974204 @default.
• W4303983644 hasConceptScore W4303983644C71924100 @default.
• W4303983644 hasConceptScore W4303983644C86803240 @default.
• W4303983644 hasConceptScore W4303983644C95457728 @default.
• W4303983644 hasLocation W43039836441 @default.
• W4303983644 hasLocation W43039836442 @default.
• W4303983644 hasLocation W43039836443 @default.
• W4303983644 hasOpenAccess W4303983644 @default.
• W4303983644 hasPrimaryLocation W43039836441 @default.
• W4303983644 hasRelatedWork W1535958986 @default.
• W4303983644 hasRelatedWork W2011428860 @default.
• W4303983644 hasRelatedWork W2124587380 @default.
• W4303983644 hasRelatedWork W2376593068 @default.
• W4303983644 hasRelatedWork W2390264150 @default.
• W4303983644 hasRelatedWork W2405509401 @default.
• W4303983644 hasRelatedWork W2417555288 @default.
• W4303983644 hasRelatedWork W2419414806 @default.
• W4303983644 hasRelatedWork W4220939315 @default.
• W4303983644 hasRelatedWork W4290436003 @default.
• W4303983644 hasVolume "6" @default.
• W4303983644 isParatext "false" @default.
• W4303983644 isRetracted "false" @default.
• W4303983644 workType "article" @default.